Sin Nombre virus full-length M segment-based DNA vaccines
AssigneeThe Government of the United States, as represented by the Secretary of the Army
InventorJay Hooper
Life of this patent
Estimating the term…
Abstract
The invention contemplates a new synthetic, codon-optimized Sin Nombre virus (SNV) full-length M gene open reading frame (ORF) that encodes a unique consensus amino acid sequence. The SNV ORF was cloned into a plasmid to form the first stable recombinant SNV full-length M gene that elicits neutralizing antibodies. The gene can be engineered into a vaccine system, and is useful to protect mammals against infection with Sin Nombre virus.
Claims19
A method for inducing an immune response against Sin Nombre virus (SNV) infection in a mammal or a bird, the method comprising administering to the mammal or the bird a composition comprising a pharmacologically acceptable carrier and an effective amount to elicit the immune response of a first plasmid comprising a first recombinant DNA construct comprising:
- (i) a first vector,
- (ii) a first promoter, and
- (iii) a first nucleic acid comprising SEQ ID NO:2 or SEQ ID NO:3, the first nucleic acid encoding SNV Gc and Gn glycoproteins, the expression of the SNV Gc and Gn glycoproteins being operably linked to the first promoter;
- the administering resulting in the expression of the SNV Gc and Gn glycoproteins.
Dependencies are inferred from the claim text.